NCCN Drugs and Biologics Compendium™ New Search Enabled
JENKINTOWN, Pa., December 19, 2006 — The National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium™ now includes an online tool to improve and optimize user searches. Cancer case managers, managed care decision-makers and other health care professionals will now be able to explore the compendium database more easily and quickly.
Based on the NCCN Clinical Practice Guidelines in Oncology™, the compendium delineates uses of drugs and biologics in the care of cancer patients, listing FDA-approved disease indications and specific NCCN recommendations for use, as well as defining levels of evidence and categories of consensus supporting the recommendations.
The compendium is divided into chapters based on cancer type. Previously, users would have to refer to multiple chapters to collect information. The new function searches across all the compendium chapters. In addition, it allows users to search via categories such as the generic and trade names of drugs and biologics as well as disease, pharmacologic class and histology.
Additional search categories include route of drug administration, ICD-9 code and NCCN Category of Consensus number. Cancer professionals can register to use the NCCN Drugs & Biologics Compendium free of charge at www.nccn.org.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. For more information, visit NCCN.org.
The NCCN Member Institutions are:
- Fred & Pamela Buffett Cancer Center
- Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
- City of Hope Comprehensive Cancer Center
- Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center
- Duke Cancer Institute
- Fox Chase Cancer Center
- Huntsman Cancer Institute at the University of Utah
- Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- Mayo Clinic Cancer Center
- Memorial Sloan Kettering Cancer Center
- Moffitt Cancer Center
- The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
- Roswell Park Cancer Institute
- Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
- St. Jude Children's Research Hospital/The University of Tennessee Health Science Center
- Stanford Cancer Institute
- University of Alabama at Birmingham Comprehensive Cancer Center
- UC San Diego Moores Cancer Center
- UCSF Helen Diller Family Comprehensive Cancer Center
- University of Colorado Cancer Center
- University of Michigan Comprehensive Cancer Center
- The University of Texas MD Anderson Cancer Center
- University of Wisconsin Carbone Cancer Center
- Vanderbilt-Ingram Cancer Center
- Yale Cancer Center/Smilow Cancer Hospital